(b) Other income, net represents the net gain on the sale of a manufacturing facility in Japan.
Wyeth calculates net income before certain significant items by excluding the after-tax effect of items considered by management to be unusual from the net income reported under generally accepted accounting principles (GAAP). Wyeth's management uses this measure to manage and evaluate the Company's performance and believes it is appropriate to disclose this non-GAAP measure to assist investors with analyzing business performance and trends. Wyeth's management believes that excluding these items from the Company's results provides a more appropriate view of the Company's operations for the accounting periods presented. These measures should not be considered in isolation or as a substitute for the results of operations and diluted earnings per share prepared in accordance with GAAP.
Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
Additional information regarding Wyeth's product sales may be accessed on the Company's Internet Web site at http://www.wyeth.com by clicking on the "Investor Relations" hyperlink.
The statements in this press release and on the related conference call
that are not historical facts, including our revised 2008 financial
guidance, are forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially from
those expressed or implied by such statements. In particular, if the
Copyright©2008 PR Newswire.
All rights reserved